Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 425-432 , August 2009

Immunoassays for the incretin hormones GIP and GLP-1

  • Carolyn F. Deacon, PhD (Doctor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Biomedical Sciences, Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark. Tel.: +45 3532 7523; Fax: +45 3532 7537.
    • ,
  • Jens J. Holst, MD (Professor)

References 

  1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–2157
  2. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007;87:1409–1439
  3. Creutzfeldt W. The incretin concept today. Diabetologia. 1979;16:75–85
  4. Holst JJ, Bersani M. Assays for peptide products of somatostain gene expression. Methods in Neurosciences. 1991;5:3–22
  5. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 1993;302:716–718
  6. Rouille Y, Westermark G, Martin SK, et al. Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells. Proceedings of the National Academy of Sciences of the United States of America. 1994;91:3242–3246
  7. Zhu X, Zhou A, Dey A, et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proceedings of the National Academy of Sciences of the United States of America. 2002;99:10293–10298
  8. Ugleholdt R, Zhu X, Deacon CF, et al. Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1. Endocrinology. 2004;145:1349–1355
  9. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry. 1993;214:829–835
  10. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. The Journal of Clinical Endocrinology and Metabolism. 1995;80:952–957
  11. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126–1131
  12. Dai H, Gustavson SM, Preston GM, et al. Non-linear increase in GLP-1 levels in response to DPP-IV inhibition in healthy adult subjects. Diabetes, Obesity & Metabolism. 2008;10:506–513
  13. Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–613
  14. Deacon CF, Plamboeck A, Møller S, et al. GLP-1-(9–36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. American Journal of Physiology. Endocrinology and Metabolism. 2002;282:E873–E879
  15. Meier JJ, Gethmann A, Nauck MA, et al. The glucagon-like peptide-1 metabolite GLP-1-(9–36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. American Journal of Physiology. Endocrinology and Metabolism. 2006;290:E1118–E1123
  16. Elahi D, Egan JM, Shannon RP, et al. GLP-1 (9–36) amide, cleavage product of GLP-1 (7–36) amide, is a glucoregulatory peptide. Obesity (Silver Spring). 2008;16:1501–1509
  17. Nikolaidis LA, Elahi D, Shen YT, et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. American Journal of Physiology. Heart and Circulatory Physiology. 2005;289:H2401–H2408
  18. Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia-reperfusion injury in rat heart. Regulatory Peptides. 2008;146:243–249
  19. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340–2350
  20. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7–36 amide and glucagonlike peptide-1 7–37 in healthy subjects are indistinguishable. Diabetes. 1993;42:658–661
  21. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7–36: a physiological incretin in man. Lancet. 1987;2:1300–1304
  22. Hendrick GK, Gjinovci A, Baxter LA, et al. Glucagon-like peptide-I-(7–37) suppresses hyperglycemia in rats. Metabolism. 1993;42:1–6
  23. Ørskov C, Rabenhøj L, Wettergren A, et al. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes. 1994;43:535–539
  24. Holst JJ, Bersani M, Johnsen AH, et al. Proglucagon processing in porcine and human pancreas. The Journal of Biological Chemistry. 1994;269:18827–18833
  25. Gutniak MK, Juntti-Berggren L, Hellstrom PM, et al. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care. 1996;19:857–863
  26. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005;48:612–615
  27. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regulatory Peptides. 1995;58:149–156
  28. Plamboeck A, Holst JJ, Carr RD, et al. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005;48:1882–1890
  29. Inagaki N, Seino Y, Takeda J, et al. Gastric inhibitory polypeptide: structure and chromosomal localization of the human gene. Molecular Endocrinology. 1989;3:1014–1021
  30. Ugleholdt R, Poulsen ML, Holst PJ, et al. Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. The Journal of Biological Chemistry. 2006;281:11050–11057
  31. Deacon CF, Nauck MA, Meier J, et al. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. The Journal of Clinical Endocrinology and Metabolism. 2000;85:3575–3581
  32. Deacon CF, Plamboeck A, Rosenkilde MM, et al. GIP-(3–42) does not antagonize insulinotropic effects of GIP at physiological concentrations. American Journal of Physiology. Endocrinology and Metabolism. 2006;291:E468–E475
  33. Krarup T, Holst JJ. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regulatory Peptides. 1984;9:35–46
  34. Krarup T. Immunoreactive gastric inhibitory polypeptide. Endocrine Reviews. 1988;9:122–134
  35. Ørskov C, Jeppesen J, Madsbad S, et al. Proglucagon products in the plasma of non-insulin dependent diabetics and nondiabetic controls in the fasting state and following oral glucose and intravenous arginine. The Journal of Clinical Investigation. 1991;87:415–423
  36. Ahrén B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2078–2084
  37. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clinical Pharmacology & Therapeutics. 2005;78:675–688
  38. Theodorakis MJ, Carlson O, Muller DC, et al. Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in impaired glucose tolerance. Diabetes Care. 2004;27:1692–1698

PII: S1521-690X(09)00025-6

doi: 10.1016/j.beem.2009.03.006

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 425-432 , August 2009

Article Tools

* Image Usage & Resolution